Navigation Links
MiMedx Exceeds Revenue Goal for First Quarter of 2012
Date:4/4/2012

KENNESAW, Ga., April 4, 2012 /PRNewswire/ -- MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that the Company has slightly exceeded its revenue goal for the first quarter of 2012. The Company's revenue goal for the first quarter 2012 was $3.6 million.

The Company also reported that several large orders were received late in the quarter that will be shipped early in April, and the revenue for these shipments will be reflected in the Company's financial results for the second quarter 2012.

"At this stage in our early and rapid growth, predicting quarterly revenue with any degree of accuracy is very difficult," said Parker H. "Pete" Petit, Chairman and CEO.  "We have all worked very hard to achieve these results, and we are pleased that we now have two sequential quarters where we have met or exceeded our revenue goals.  Based on the momentum we have created, we believe our previously communicated revenue goal of $23 million for full year 2012 is still attainable."

About MiMedx

MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane.  "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix® and CollaFix™, and our tissue technologies, AmnioFix® and EpiFix®. Our tissue technologies, processed from the human amniotic membrane, utilize our proprietary Purion® Process that was developed by our wholly-owned subsidiary, Surgical Biologics, to produce a safe, effective and minimally manipulated implant for homologous use. Surgical Biologics
'/>"/>

SOURCE MiMedx Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. MiMedx Group Announces Temporary Trading Symbol Designation
2. MiMedx Group, Inc. to Present at Noble Financial Sixth Annual Equity Conference
3. MiMedx Group, Inc. Announces Release Date For Third Quarter Results
4. MiMedx Group, Inc. to Present at the 13th Annual Needham Growth Conference
5. MiMedx to Attend American Academy of Orthopedic Surgeons Annual Meeting
6. MiMedx Announces Launch of AmnioFix™
7. MiMedx Group, Inc. to Present at the 10th Annual Needham Healthcare Conference
8. MiMedx Group Announces 2010 Results
9. MiMedx Group Announces First Quarter 2011 Results
10. MiMedx Group, Inc. to Present at the Noble Financial Capital Markets Seventh Annual Equity Conference
11. MiMedx Group Completes $5,000,000 Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... N.J. (PRWEB) December 17, 2014 ... (Euronext: IPN; ADR: IPSEY), today announced ... (referred to as Somatuline®) was approved by the ... treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult ... advanced or metastatic disease to improve progression-free survival ...
(Date:12/17/2014)... Texas (PRWEB) December 17, 2014 ... on Global Quartz Tubing industry. For an overview ... definition, classification, application, industry chain structure, industry overview, ... quartz tubing industry has witnessed rapid ... a number of acquisitions. This report mentions quartz ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... , Dec. 16, 2014  Vermillion, Inc. (NASDAQ: ... on gynecologic disease, today announced the next step in ... premier bio-analytics solutions provider with the naming of current ... and Chief Executive Officer, while current Chairman of the ... to serve as Chairman. These changes are effective January ...
Breaking Biology Technology:Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 82020 Quartz Tubing Market: Global Development & Forecasts Analysis Now at DeepResearchReports.com 2ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4
(Date:11/21/2014)... According to a new market research report ... Control, Intrusion Detection, Parking Management, Under Vehicle Inspection), End ... - Global Forecasts to 2020", published by MarketsandMarkets, The ... $25 Billion in 2014 and is expected to reach ... 8.69%. Browse 116 market data Tables and ...
(Date:11/18/2014)... Nov. 18, 2014  The Secure Identity & ... today jointly announce the formation of The Airport ... its Identity and Biometric Entry and Exit ... received official support from BORDERPOL, the international non-profit ... and provide expertise regarding border security, traveler and ...
(Date:11/12/2014)... Nov. 12, 2014 Crossmatch™, a leading provider ... U.are.U ® fingerprint readers have been deployed throughout ... Central Mexico . The bakery chain implemented ... payroll issues caused by employees clocking in for each ... fingerprint readers, Montparnasse relied on paper timecards and a ...
Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... a fungal infection which is one of the major causes of ... PLoS Pathogens , funded by the Wellcome Trust and the ... evolved and spread out of Africa and into Asia. ... fungi. One particular strain of the fungus known as ...
... April 1, 2011 Aware, Inc. (NASDAQ: AWRE ... telecommunications and biometrics industries, today announced that Edmund C. Reiter ... Executive Officer and director of the board of the company ... and Kevin T. Russell, General Counsel have been named co-CEOs ...
... Fla., April 6, 2011 Ceelox, Inc. (OTCBB: CELO) ... PC Edition which operates on computers running the Windows ... has redesigned their authentication approach to leverage the recent ... Biometric Framework (WBF) provides support for fingerprint biometric devices ...
Cached Biology News:Scientists track evolution and spread of deadly fungus, one of the world's major killers 2Aware, Inc. Announces Resignation of Chief Executive Officer 2Aware, Inc. Announces Resignation of Chief Executive Officer 3Ceelox Offers Beta Release of Ceelox ID 7 for Personal Computers 2
... depletion cocktail is tailored to ... suspensions of rat spleen cells. ... StemSep (or compatible 0.5 Tesla) ... T cell content of the ...
CleanCut agarose is used to prepare genomic DNA plugs for use in pulsed field gel electrophoresis (PFGE) applications. Supplied as a 12 ml solution of 2% agarose....
... an intelligent full microplate washer with a 96 ... instrument gives you the best of two worlds ... , Performance ,Separate wash and aspiration ... A dispense precision of better than 2% CV ...
... culture scale-up, these culture chambers produce cell ... 9 range and are useful alternatives ... • High mechanical • strength and structural ... shipping • Certified nonpyrogenic and sterilized by ...
Biology Products: